Skip to main content

Table 4 Univariate Analysis of predictors for Loco-regional recurrence (LRR), distant metastasis (DM), any progression and overall survival (OS) for patients with limited stage small cell lung cancer (LS-SCLC) treated with chemoradiation, (n = 105)

From: The impact of quantitative CT-based tumor volumetric features on the outcomes of patients with limited stage small cell lung cancer

CategoryLRRIn-field LRRDMAny progressionOS
HR (95% CI)p-valueHR (95% CI)p-valueHR (95% CI)p-valueHR (95% CI)p-valueHR (95% CI)p-value
Gender          
 Femalea
 Male0.75 (0.39–1.44)0.390.80 (0.38–1.71)0.570.70 (0.41–1.21)0.200.70 (0.43–1.16)0.170.50 (0.32–0.80)0.003c
Age (continuous)0.97 (0.94–1.01)0.200.95 (0.91–0.99)0.041.00 (0.97–1.03)0.960.99 (0.96–1.02)0.561.01 (0.98–1.04)0.46
Race          
 Whitea
 African American0.65 (0.09–4.76)0.670.991.44 (0.45–4.64)0.541.22 (0.38–3.89)0.741.31 (0.47–3.66)0.61
0.37 (0.05–2.67)   0.89 (0.28–2.86) 0.71 (0.22–2.28) 1.00 (0.36–2.76) 
 Otherb 0.320.47 (0.06–3.74)0.46 0.84 0.60 0.99
Performance score          
 0a
 ≥12.00 (0.94–4.25)0.071.61 (0.71–3.66)0.252.92 (1.46–5.84)0.002c2.90 (1.53–5.48)0.001c3.05 (1.70–5.45)< 0.001c
Smoking history          
 Currenta 
 Former0.71 (0.36–1.39)0.321.05 (0.61–1.79)0.870.99 (0.60–1.65)0.971.15 (0.72–1.82)0.56
1.92 (0.45–8.19)   0.52 (0.07–3.83) 1.16 (0.28–4.81) 0.99 (0.24–4.1) 
 Never 0.38 0.52 0.84 0.99
Pack-years1.01 (0.99–1.02)0.211.00 (0.99–1.02)0.961.01 (1.00–1.02)0.111.01 (0.99–1.01)0.201.01 (1.00–1.02)0.12
T stage          
T0–1a
T2–40.66 (0.34–1.28)0.220.93 (0.44–1.99)0.850.64 (0.37–1.12)0.120.64 (0.38–1.08)0.090.67 (0.41–1.10)0.11
N stage          
N0–1a
N2–35.47 (0.75–39.93)0.091.64 (0.59–4.56)0.342.06 (0.75–5.67)0.161.35 (0.62–2.95)0.45
Overall stage          
IIIBa
IA-IIIA0.59 (0.28–1.25)0.170.32 (0.13–0.78)0.01c0.68 (0.36–1.28)0.230.69 (0.39–1.22)0.200.73 (0.44–1.22)0.23
1.34 0.33 (0.12–0.94) 1.45 (0.75–2.78) 1.37 (0.73–2.55) 0.97 (0.54–1.79) 
(0.61–2.95)         
IIIC 0.47 0.04 0.26 0.33 0.95
Induction chemotherapy          
 Yes1.77 (0.69–4.53)0.241.67 (0.58–4.80)0.341.33 (0.65–2.73)0.431.43 (0.73–2.82)0.301.65 (0.87–3.14)0.12
 Noa 
Concurrent chemotherapy          
 Yes0.43 (0.17–1.11)0.080.89 (0.21–3.77)0.880.40 (0.18–0.90)0.030.33 (0.16–0.68)0.003c0.29 (0.15–0.54)< 0.001c
 Noa  
PCI          
 Yes0.71 (0.37–1.36)0.301.21 (0.53–2.74)0.650.40 (0.23–0.68)< 0.001c0.44 (0.27–0.73)0.001c0.37 (0.23–0.59)< 0.001c
 Noa
Median RT dose0.97 (0.93–1.01)0.150.94 (0.90–0.99)0.02c1.03 (1.00–1.06)0.041.01 (0.99–1.04)0.341.01 (0.99–1.04)0.34
RT fractionation          
 Dailya
 BID1.13 (0.59–2.13)0.721.49 (0.70–3.16)0.300.68 (0.40–1.17)0.160.76 (0.46–1.26)0.290.64 (0.40–1.02)0.06
Tumor volume (cm3)1.00 (1.00–1.00)0.211.00 (1.00–1.00)0.111.00 (1.00–1.00)0.611.00 (1.00–1.00)0.231.00 (1.00–1.00)0.90
Maximum 2D tumor diameter axial (cm)1.10 (1.00–1.20)0.02c1.10 (0.90–1.20)0.081.10 (0.90–1.20)0.091.10 (0.90–1.20)0.051.10 (0.90–1.10)0.14
Maximum 2D tumor diameter coronal (cm)1.10 (1.00–1.20)0.01c1.10 (1.00–1.20)0.008c1.10 (1.00–1.20)0.031.10 (1.00–1.10)0.02c1.10 (0.90–1.10)0.11
Maximum 2D tumor diameter sagittal (cm)1.10 (1.00–1.20)0.01c1.10 (1.00–1.20)0.01c1.10 (0.90–1.10)0.141.10 (0.90–1.10)0.101.00 (0.90–1.10)0.38
Maximum 3D tumor diameter (cm)1.10 (1.00–1.20)0.003c1.10 (1.00–1.20)0.007c1.10 (1.00–1.20)0.021.10 (1.00–1.10)0.008c1.10 (1.00–1.20)0.03
  1. areference value; b Asian, not available and other; Bolded values indicate significance, p<0.05
  2. cMeets significance after adjustment for hypothesis testing using a Benjamini-Hochberg FDR of 0.1